Christof Hänsli (Christof Haensli)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 7

Top Topics

Vascular Endothelial Growth Factor

Cross Sectional

Ankylosing Spondylitis

Optical Coherence Tomography

Top Venues

Life (Basel, Switzerland)

Journal of clinical medicine

Ocular immunology and inflammation

Journal of ophthalmology

This page only lists publications with an associated author ORCID identifier.

Publications

Christof Hänsli, Christin Schild, Isabel Pfister, Justus Gerhard Garweg
Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis. Life (Basel, Switzerland) 13 (3) (2023)
Christof Hänsli, Christin Schild, Isabel Pfister, Justus Gerhard Garweg
Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis. Life (Basel, Switzerland) 13 (3) (2023)
Christof Hänsli, Christin Schild, Isabel Pfister, Justus Gerhard Garweg
Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis. Life (Basel, Switzerland) 13 (3) (2023)
Christof Hänsli, Suijana Lavan, Isabel B Pfister, Christin Schild, Justus G Garweg
Outer retinal features in OCT predict visual recovery after primary macula-involving retinal detachment repair. PloS one 17 (5) (2022)
Christof Hänsli, Katrin Fasler, Barthelmes Daniel, Sandrine Anne Zweifel
Characterizing Flow and Structure of Diabetic Retinal Neovascularization after Intravitreal Anti-VEGF Using Optical Coherence Tomography Angiography: A Pilot Study. Journal of ophthalmology 2021 (2021)
Christof Hänsli, Isabel B Pfister, Justus Gerhard Garweg
Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes. Journal of clinical medicine 10 (12) (2021)
Justus Gerhard Garweg, Christof Hänsli
Pitfalls in the Interpretation of Intraocular Inflammation in Response to Intravitreal Brolucizumab Injection. Ocular immunology and inflammation (2021)